UroGen Pharma (URGN) Asset Writedowns and Impairment (2022)
UroGen Pharma's (URGN) quarterly Asset Writedowns and Impairment came in at $255000.0 in Q4 2022, down 27.14% on a QoQ basis from $350000.0 in Q3 2022.
Powered by 
Analysis
UroGen Pharma (URGN) Asset Writedowns and Impairment (2022) Analysis & Trends
UroGen Pharma (URGN) has 1 years of Asset Writedowns and Impairment data on file, last reported at $255000.0 in Q4 2022.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $255000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2023 was $605000.0 (changed 0.0% YoY) and the FY2022 annual result came in at $870000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment eased to $255000.0 in Q4 2022, from $350000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $350000.0 in Q3 2022 to a low of $255000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | UroGen Pharma | 2.23 Bn | 2.12 Bn | 65.88 Mn |